Biodesix announces publication highlighting interim data from the insight study assessing the clinical effectiveness of veristrat® proteomic test in the journal of immunotherapy of cancer

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study insight (clinical effectiveness assessment of veristrat® testing and validation of immunotherapy tests in nsclc subjects) (nct03289780) utilizing its novel predictive and prognostic blood-based host immune classifier (the veristrat test) to stratify immune che
BDSX Ratings Summary
BDSX Quant Ranking